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Objectives This study sought to assess whether plasminogen, which is homologous to lipoprotein (a) [Lp(a)], contains proin-
flammatory oxidized phospholipids (OxPL) and whether this has clinical relevance.
Background OxPL measured on apolipoprotein B-100 (OxPL/apoB), primarily reflecting OxPL on Lp(a), independently predict
cardiovascular disease (CVD) events.
Methods The authors examined plasminogen from commercially available preparations and plasma from chimpanzees;
gorillas; bonobos; cynomolgus monkeys; wild-type, apoE/, LDLR/, and Lp(a)-transgenic mice; healthy hu-
mans; and patients with familial hypercholesterolemia, stable CVD, and acute myocardial infarction (AMI). Phos-
phocholine (PC)-containing OxPL (OxPC) present on plasminogen were detected directly with liquid chromatography–
mass spectrometry (LC-MS/MS) and immunologically with monoclonal antibody E06. In vitro clot lysis assays
were performed to assess the effect of the OxPL on plasminogen on fibrinolysis.
Results LC-MS/MS revealed that OxPC fragments were covalently bound to mouse plasminogen. Immunoblot, immuno-
precipitation, density gradient ultracentrifugation, and enzyme-linked immunosorbent assay analyses demon-
strated that all human and animal plasma samples tested contained OxPL covalently bound to plasminogen. In
plasma samples subjected to density gradient fractionation, OxPL were present on plasminogen (OxPL/plasmin-
ogen) in non-lipoprotein fractions but on Lp(a) in lipoprotein fractions. Plasma levels of OxPL/apoB and OxPL/
apo(a) varied significantly (25) among subjects and also strongly correlated with Lp(a) levels. In contrast,
OxPL/plasminogen levels were distributed across a relatively narrow range and did not correlate with Lp(a). En-
zymatic removal of OxPL from plasminogen resulted in a longer lysis time for fibrin clots (16.25 vs. 11.96 min,
p  0.007). In serial measurements over 7 months, OxPL/plasminogen levels did not vary in normal subjects or
in patients with stable CVD, but increased acutely over the first month and then slowly decreased to baseline in
patients following AMI.
Conclusions These data demonstrate that plasminogen contains covalently bound OxPL that influence fibrinolysis. OxPL/plas-
minogen represent a second major plasma pool of OxPL, in addition to those present on Lp(a). OxPL present on
plasminogen may have pathophysiological implications in AMI and atherothrombosis. (J Am Coll Cardiol 2012;
59:1426–37) © 2012 by the American College of Cardiology Foundation
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April 17, 2012:1426–37 Oxidized Phospholipids, Plasminogen, and AMIPlasminogen plays a key role in the fibrinolytic system and
has also been implicated in several other pathophysiological
properties, including tissue remodeling, angiogenesis, em-
bryogenesis, tumor metastasis, infections, wound healing,
and leukocyte migration (1). Plasminogen consists of 5
tandem kringle domains and a protease domain. It is
activated to plasmin by physiological activators, such as
tissue-type plasminogen activator (tPA), and in turn, plas-
min degrades fibrin-rich thrombi through a functional serine
protease domain. Kringles are common motifs in coagulation
and growth factors and in apolipoprotein (a) (apo(a)).
See page 1438
Lipoprotein (a) (Lp(a)) is composed of apo(a) covalently
bound via a single disulfide bond on kringle IV type 9 to
apolipoprotein B-100 (apoB) of low-density lipoprotein
(LDL). Apo(a) is highly homologous to plasminogen and is
believed to have evolved from duplication of parts of the
plasminogen gene present on the long arm of chromosome 6.
The apo(a) gene sits opposite the plasminogen gene on
chromosome 6q26–27 and consists of multiple KIV repeats, of
which subtype KIV-2 is present in multiple and variable
numbers, KV, and an inactive protease domain due to a
Ser561-Ile562 substitution for Arg561-Val562 present on plas-
minogen (2). Unlike plasminogen, which is present widely
across species, apo(a) appeared late during evolution, approxi-
mately 40 to 60 million years ago, and is present only in
humans, non-human primates, and old world monkeys, as well
as an unrelated version in European hedgehogs. Lp(a) is now
generally recognized as a causal, independent, genetic cardio-
vascular risk factor for coronary artery disease (CAD) and
myocardial infarction (3–5).
We made the initial observation that Lp(a) is a prefer-
ential lipoprotein carrier of oxidized phospholipids (OxPL)
in humans (6–10). We developed an enzyme-linked immu-
nosorbent assay (ELISA) that quantitates OxPL on human
apoB particles (OxPL/apoB), which primarily reflects the
presence of OxPL on Lp(a). We have demonstrated that
OxPL/apoB levels reflect changes in vascular and endothe-
lial function and coronary calcium, identified the presence
and progression of carotid and femoral atherosclerosis, and
angiographically determined CAD (8,11). Elevated OxPL/
apoB levels occur following acute coronary syndromes
(ACS) (6) and percutaneous coronary intervention (12) and
predict the occurrence of new cardiovascular disease (CVD)
events in previously healthy subjects (3,13). Thus, OxPL/
apoB appears to reflect the adverse consequences of Lp(a)
on cardiovascular outcomes, but are also independently
associated with CVD risk above and beyond Lp(a) levels
(reviewed in Taleb et al. [14]).
In this study, we examine the hypothesis that plasminogen,
due to its high homology to apo(a), may also contain OxPL
and assess whether OxPL levels on plasminogen vary with
differences in plasma Lp(a) levels in patients with familialhypercholesterolemia (FH), affect
fibrinolysis, and vary temporally in
patients with stable CAD and fol-
lowing ACS.
Methods
A detailed description of the
Methods section is available in
the Online Appendix.
Human subjects. Human plasma
was obtained from healthy vol-
unteers, patients with heterozy-
gous FH with highly elevated
LDL cholesterol levels but vary-
ing Lp(a) levels, and serial sam-
ples from patients with stable
CAD and acute myocardial in-
farction (AMI) (6).
Source of animal plasma samples.
Plasma samples from bonobos,
chimpanzees, gorillas, cynomolgus
monkeys, and wild-type, trans-
genic Lp(a) (15), apoE/, and
LDLR/ mice were obtained
for measurement of OxPL on
plasminogen.
Plasminogen and antibodies.
Murine and human plasminogen
were purchased commercially. A
rabbit polyclonal anti-human plas-
minogen antibody (Santa Cruz Bio-
technology, Santa Cruz, California)
raised against amino acids 16 to
105 at the N-terminal end of
human plasminogen, a sequence
not present in apo(a), was used for immunoblot analysis to
avoid cross-reactivity with apo(a). A murine monoclonal
anti-human plasminogen antibody not cross-reacting with
apo(a) and a polyclonal, biotinylated, guinea pig anti-
plasminogen antibody were used as capture and detection
antibodies, respectively. Monoclonal antibodies MB47,
binding human apoB, LPA4 binding apo(a), and E06
binding the phosphocholine (PC) headgroup of OxPL were
previously described (12).
Tandem liquid chromatography–mass spectrometry analysis
of OxPL on mouse plasminogen. Liquid chromatography–
mass spectrometry (LC-MS/MS) was utilized to assess the
covalent binding of PC-containing OxPL on mouse plas-
minogen (Haematologic Technologies, Essex Junction,
Vermont) using a triple quadruple instrument Thermal
TSQ Vantage mass spectrometer (Thermo Fisher Scientific,
Waltham, Massachusetts) coupled with a Waters NanoAc-
quity autosampler/UPLC system (Waters Corporation,
Milford, Massachusetts), as previously described (16). Full-
Abbreviations
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infarction
ANOVA  analysis of
variance
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disease
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out to identify a product ion of m/z 184, which is charac-
teristic for the PC headgroup.
Immunoblot analyses. Non-reducing sodium dodecyl
sulfate–polyacrylamide gel electrophoresis was carried out
using precast gradient gels with 4% to 12% polyacrylamide
concentrations.
Density gradient ultracentrifugation and OxPL on lipo-
proteins. Isopycnic density gradient ultracentrifugation
was used to fractionate plasma, providing 24 fractions plus
the non-lipoprotein plasma “bottom” fraction as previously
described (10). OxPL on apoB (OxPL/apoB) (14) and
OxPL on apo(a) (OxPL/apo(a)) (17) were measured as
described.
ELISA to measure plasminogen levels and OxPL on
plasminogen. To measure plasminogen levels, microtiter
well plates (Dynex Technologies, Chantilly, Virginia) were
incubated with a mouse monoclonal anti-human plasmin-
ogen antibody (Meridian Life Science, Saco, Maine) at 5
g/ml overnight at 4°C, the plates washed, human plasma
added (1:32,000 dilution), and plasminogen detected with
biotinylated guinea pig anti-human plasminogen antibody
using chemiluminescence ELISA.
OxPL on plasminogen (OxPL/plasminogen) was deter-
mined in a similar manner except the plasma dilution was
1:400 and biotinylated EO6 was the detection antibody. This
assay normalized all wells to the same amount of plasminogen
and is therefore independent of plasma plasminogen levels.
Immunoprecipitation. To assess whether OxPL are phys-
ically associated with plasminogen, increasing amounts of
the murine monoclonal anti-human plasminogen antibody
(Meridian), not cross-reacting with apo(a), were added to
human plasma to preferentially precipitate plasminogen.
Plasminogen, OxPL/plasminogen, Lp(a), and OxPL/apo(a)
were then measured in the supernatant.
Phospholipase A2 treatment of plasminogen. Plasmino-
en, free of Lp(a), was purified from fresh-frozen plasma
sing lysine-Sepharose affinity chromatography and incubated
ith or without 35 U/ml of phospholipase A2 (PLA2) at 37°C
or 90 min and then PLA2 quenched by the addition of
phenylmethanesulfonylfluoride. The treated plasminogen was
then isolated by lysine-Sepharose and subjected to sodium
dodecyl sulfate–polyacrylamide gel followed by silver staining
to verify the absence of degradation. OxPL removal was
confirmed by Western blot analysis using EO6.
In vitro clot lysis assay. Assays were performed in a
manner similar to that previously published (18). Fibrin
clots were formed by the addition of a solution containing 1
mg/ml purified fibrinogen and 0.66 mol/l plasminogen
(with or without PLA2 treatment) to small, separated
aliquots of CaCl2, thrombin, and tPA at final concentra-
tions of 10 mmol/l, 6 nmol/l, and 100 pmol/l, respectively.
Clot lysis at 37°C was monitored by measurement of
turbidity at 405 nm and defined as the time required to
reach the midpoint between the maximum and minimum
turbidity excursions.Determination of OxPL on coagulation factors with
kringle-like structures. To determine whether kringle do-
mains of other coagulation factors also contain OxPL
detectable by EO6, we used commercially available antibod-
ies to specifically capture prothrombin, urokinase, and tPA
in microtiter well plates from plasma of 6 healthy human
individuals, and OxPL was determined with E06.
Results
Baseline characteristics of the human study population.
The baseline characteristics of the human subjects from
whom plasma was derived for the various studies are
depicted in Table 1. The characteristics are typical of their
underlying diagnoses.
Determination of OxPL on mouse plasminogen using
LC-MS/MS. We studied mouse plasminogen (with no
possibility of Lp(a) contamination as mice do not have Lp(a))
to determine whether covalently bound OxPL-containing
phosphocholine (OxPC) were present. The presence of OxPC
on trypsin digests of plasminogen was assessed by precursor ion
scanning for m/z 184, which is the signature of PC. Since we
postulated that the OxPL were covalently bound by Schiff base
adducts between oxidized sn-2 side chains of the OxPL and
epsilon amino groups of lysine, we also examined for the
presence of OxPC on the plasminogen digests before and after
saponification with NH4OH.
As shown in Figure 1A, a number of prominent peptide
eaks containing OxPC were present in the LC-chromatogram
hen examined by precursor ion scanning mass spectrometry,
ndicating OxPC-modified peptides. More importantly, these
eaks disappeared when the protein was first saponified by
H4OH (Fig. 1B). Full-scan experiments demonstrated the
resence of similar patterns of peptides in samples with or without
H4OH pretreatment (data not shown). These results suggest
hat there are multiple, but limited, sites on plasminogen that were
ovalently modified by OxPC.
mmunoblot and ELISA analysis demonstrating OxPL
n human and murine plasminogen. We next examined
or the presence of OxPL on plasminogen from a variety of
ources by Western blotting techniques using monoclonal
06 specific for PC-containing OxPL. Polyacrylamide gel
lectrophoresis of commercially available, lysine-Sepharose
olumn purified, human and murine plasminogen, as well as
reshly procured plasma samples from wild-type, LDLR/,
apoE/, and apo(a) and Lp(a) transgenic mice (all on
standard mouse chow) was performed and the gels incu-
bated with: 1) biotinylated species-appropriate anti-
plasminogen antibodies; 2) monoclonal antibody LPA4 to
detect apo(a); and 3) monoclonal antibody EO6 to detect
OxPL. Figure 2A (left panel) demonstrates that plasmino-
gen is present in all lanes at the appropriate molecular
weight (88 to 92 kDa), as expected. Figure 2A (middle
panel) demonstrates that OxPL is present in all samples
corresponding to the molecular weight of plasminogen and
also at the appropriate molecular weight for apo(a) in lanes
w-dens
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There are no other E06-positive bands throughout the gel,
suggesting that plasminogen and apo(a)/Lp(a) are the major
protein/lipoprotein carriers of OxPL in plasma. Figure 2A
(right panel) confirms the presence of apo(a) immunoreac-
tivity, detected by antibody LPA4, in the apo(a) and Lp(a)
transgenic mouse plasma. Interestingly, Lp(a) is also present
in the commercial preparation of human plasminogen,
which undoubtedly coelutes with plasminogen on the
lysine-Sepharose columns used to purify plasminogen, since
they share similar lysine binding sites, particularly on
KIV-10. The size of the human Lp(a) is larger than in the
Lp(a) transgenic mouse, as the Lp(a)-transgenic mice ex-
press a mini apo(a) construct (19). An OxPL band corre-
sponding to the Lp(a) contaminant in the human purified
plasminogen is not visible, likely due to much higher
(50) sensitivity of LPA4 versus E06 on immunoblots, as
previously shown (7).
Figure 2B displays the plasma plasminogen and OxPL/
plasminogen in 6 healthy human subjects using a sandwich
ELISA format. It is evident that OxPL are strongly present on
plasminogen captured on the microtiter well plate. In contrast,
there is no evidence that apo(a) or apoB are present on the
captured plasminogen, ruling out nonspecific physical interac-
tions of apo(a) or apoB as potential contributions of OxPL on
plasminogen. Importantly, like Lp(a), plasminogen is not
“oxidized” per se, as supported by the observation that murine
Demographics of Human Study PopulationTable 1 Demographics of Human Study Pop
AMI
(n  8)
Age, yrs 58 13
Male/female 8/0
Coronary risk factors
Hypertension 4 (50)
Tobacco use 3 (38)
Diabetes mellitus 2 (25)
LDL cholesterol 130 mg/dl 3 (38)
HDL cholesterol 35 mg/dl 3 (38)
Medications
Statins 2 (25)
Other lipid-modifying agents 0
Beta-blockers 2 (25)
Calcium channel blockers 0
ACE inhibitors/ARB 2 (25)
Aspirin 1 (13)
Past medical history
MI 0
CHF 0
PCI 0
CABG 0
Values are mean  SD, n/n, or n (%).
ACE  angiotensin-converting enzyme; ACS  acute coronary syn
blocker; CABG  coronary artery bypass graft surgery; CAD  c
hypercholesterolemia; HDL  high-density lipoprotein; LDL  lo
coronary intervention.monoclonal antibody MDA2 (10), which recognizes malon-dialdehyde (MDA)-lysine epitopes and which are commonly
present during generalized lipid peroxidation, does not show
immunoreactivity with plasminogen.
Assessment of the presence of OxPL on plasminogen
using immunoprecipitation of human plasma. Incubat-
ing increasing amounts of a murine monoclonal anti-human
plasminogen antibody with human plasma demonstrates that at a
molar ratio of 15:1 (anti-plasminogen antibody/plasminogen),
nearly all of the plasminogen was precipitated (Fig. 3A). In
parallel, a similar decrease in OxPL/plasminogen (Fig. 3B) was
noted. In contrast, Lp(a) (Fig. 3C) and apoB (Fig. 3D)
remained in the supernatant, suggesting that OxPL were
physically associated with plasminogen. In a prior study,
we demonstrated that immunoprecipitation of Lp(a) with
LPA4 immunoprecipitated the OxPL associated with
Lp(a) (10).
Coagulation factors with kringle-like structures do not
contain OxPL. Using specific antibodies to capture plas-
minogen (5 kringles), prothrombin (factor II) (2 kringles),
tPA (2 kringles), and urokinase (1 kringle) on microtiter
well plates and adding biotinylated E06, it was demonstrated
that OxPL were only present on plasminogen (Fig. 4).
OxPL on plasminogen and lipoproteins isolated by den-
sity gradient ultracentrifugation. Plasma from 2 patients
with an Lp(a) level of 90 mg/dl were subjected to density
gradient ultracentrifugation. Direct plating of the density
fractions on microtiter well plates was used to assess the
n
ACS Study
le CAD
17)
Healthy Subjects
(n  18)
FH Patients
(n  15)
 11 37 7 42 19
3/4 11/7 9/6
(53) 1 (5) 1 (7)
(12) 1 (5) 4 (27)
(24) 0 0
(12) 5 (26) 14 (93)
(24) 0 8 (53)
(53) 1 (5) 8 (53)
(18) 0 8 (53)
(24) 1 (5) 6 (40)
(24) 0 2 (13)
(18) 0 4 (27)
(100) 2 (11) 5 (33)
(24) 0 4 (27)
(6) 0 0
(18) 0 1 (7)
(12) 0 5 (33)
s); AMI  acute myocardial infarction; ARB  angiotensin receptor
y artery disease; CHF  congestive heart failure; FH  familial
ity lipoprotein; MI  myocardial infarction; PCI  percutaneousulatio
Stab
(n 
68
1
9
2
4
2
4
9
3
4
4
3
17
4
1
3
2
drome(
oronarpresence of apo(a) and apoB in each fraction. A set of capture
m1430 Leibundgut et al. JACC Vol. 59, No. 16, 2012
Oxidized Phospholipids, Plasminogen, and AMI April 17, 2012:1426–37assays was also performed as described in the previous text,
where specific antibodies for plasminogen, Lp(a), and apoB
were used to capture these particles, respectively. Specific
antibodies were then used to detect the presence of plasmin-
ogen, Lp(a), apoB, and OxPL on the captured proteins or
lipoproteins. An example from 1 patient shows that plasmin-
ogen was present in the heaviest density fractions and Lp(a)
present in the modestly dense fractions (density 1.050 to 1.090
g/ml, corresponding to fractions 11 to 15), as expected. These
aliquots also directly correspond to the presence of OxPL on
plasminogen or Lp(a). ApoB is widely distributed across the
density range, but OxPL/apoB is primarily present in the Lp(a)
density range, consistent with the fact that these apoB particles
are associated with Lp(a) and not LDL (Fig. 5). The OxPL/
apo(a) and OxPL/apoB and Lp(a) data are also consistent with
prior observations from a similar analysis (10).
We also examined whether plasminogen levels and
OxPL/plasminogen varies among patients with different
Lp(a) levels. We analyzed 15 subjects with FH segregated
evenly into 3 groups of 5 subjects each, according to low (10 3
g/dl), intermediate (42 5 mg/dl), and high (103 8 mg/dl)
Lp(a) levels (p  0.0001 by analysis of variance [ANOVA])
(Fig. 6). We also assessed the non–lipoprotein-containing
fraction (“bottom” fraction) for plasminogen and OxPL/
Figure 1 LC-MS/MS Analysis of Mouse Plasminogen
Detection of oxidized phospholipids (OxPL) containing phosphocholine (PC) on plas
scanning (PIS) for phosphocholine (m/z 184) was carried out on LC-separated pep
NH4OH treatment (B). See the Methods section for details.plasminogen. It is noted that the plasma OxPL/apo(a) levels(p  0.0001 by ANOVA) track nearly identically with the
plasma Lp(a) levels (p  0.0001 by ANOVA)
(Figs. 6A and 6B), but vary significantly (25-fold) among
groups. However, by contrast, plasminogen levels (p  0.08
by ANOVA) and OxPL/plasminogen (p  0.14 by
ANOVA) are not significantly different among the groups
(Figs. 6C and 6D) and vary minimally (2-fold). As a
confirmation of the presence of plasminogen (p  0.28 by
ANOVA) and OxPL/plasminogen (p  0.71 by ANOVA)
in non-lipoprotein fractions, we also evaluated the “bottom”
density fraction which contains all the non-lipoprotein
plasma proteins, and the findings are similar to the plasma
data for plasminogen (Figs. 6E and 6F).
OxPL/plasminogen of monkeys and apes. Plasminogen
and OxPL/plasminogen were measured in plasma from 6
cynomolgus monkeys, 14 gorillas, 5 chimpanzees, and 4
bonobos using the same assays used for the human plasma.
OxPL was detected on the plasminogen of each species, and
the OxPL/plasminogen levels corresponded to the level of
plasminogen (Online Fig. 1). Comparison of the relative
differences between groups cannot be made because differences
in the affinities of the capture and detection antibodies among
the species may exist, which were not directly tested due to the
en by liquid chromatography–mass spectrometry (LC-MS/MS). Precursor ion
of plasminogen following trypsin digestion without NH4OH treatment (A) and withminog
tidesdifficulty in obtaining purified plasminogen from apes.
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To enzymatically remove the covalently bound OxPL,
purified human glu-plasminogen was treated with PLA2,
nd the OxPL was successfully removed as documented
y immunoblotting with E06 (Fig. 7, inset). The ability
f plasminogen species with and without OxPL to
egrade fibrin clots was then tested with a well-validated
n vitro clot assay (18). This demonstrates that the
nzymatic removal of the OxPL component (without
egrading the plasminogen protein integrity) results in a
6% longer clot lysis time (975  41.2 s vs. 718  6.6 s,
p  0.007, or 16.25 min vs. 11.96 min) compared with
the intact plasminogen containing OxPL (Fig. 7). Clot
Figure 2 OxPL on Plasminogen and Apo(a) Demonstrated by W
Presence of PC-containing OxPL on plasminogen and apolipoprotein (a) [Lp(a)] dem
niques. (A) Immunoblot. Left panel: Specific binding of polyclonal rabbit anti-huma
apo(a) in transgenic mice detected by monoclonal EO6. Right panel: Apo(a) detec
plasminogen (OxPL/plasminogen), or malondialdehyde associated with plasminoge
minogen (apo(a) or apoB/plasminogen) by ELISA. Results are mean  SEM and e
groups. Lp(a)  lipoprotein (a); wt  wild type; other abbreviations as in Figure 1.lysis time is defined as the transition midpoint that ishalfway between the minimum and maximum excursions.
This suggests that the presence of OxPL on plasminogen
facilitates clot lysis.
Temporal trends in plasminogen, OxPL/plasminogen in
normal human subjects, patients with CAD and ACS. To
assess changes with time, we measured plasminogen and
OxPL/plasminogen levels in serial time points over 7
months in 18 healthy volunteers, 17 patients with stable
CAD, and 8 patients with AMI, 6 of which had an
ST-segment elevation myocardial infarction (Fig. 8). Inter-
estingly, the baseline levels of plasminogen and OxPL/
plasminogen were lower in the AMI patients compared
with the healthy subjects and patients with stable CAD
rn Blotting and ELISA
ated by Western Blotting and enzyme-linked immunosorbent assay (ELISA) tech-
minogen antibody to plasminogen. Middle panel: OxPL on plasminogen and
monoclonal LPA4. (B) Detection of plasminogen, and the presence of OxPL on
A/plasminogen), or apo(a) or apolipoprotein B-100 (apoB) associated with plas-
ed as relative light units (RLU)/100 ms. ***p  0.001 compared with the othereste
onstr
n plas
ted by
n (MD
xpress(44,432 5,184 relative light units [RLU], 64,649 9,043
A
p
o
l
A
n
8
7
e
b
t
O
0
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NOVA) (Fig. 8A). These RLU values correspond to
lasminogen levels of approximately 15 to 20 mg/dl based
n the standard curve of the plasminogen ELISA. Baseline
evels of OxPL/plasminogen levels were also lower in the
MI patients compared with patients with stable CAD but
ot compared with healthy subjects (56,369 19,290 RLU,
5,809  30,475 RLU, 70,795  15,172 RLU, respec-
tively, p  0.015 by ANOVA) (Fig. 8B).
Evaluating the data as a mean percent change over time
across each group by ANOVA, the plasminogen levels were
significantly elevated in the AMI group at discharge (p 
0.01) and after 30 days (p 0.01), but not after 120 days and
months (Fig. 8B). The OxPL/plasminogen levels were also
levated at discharge (p  0.01) and after 30 days (p  0.05),
Figure 3 Assessment of the Presence of OxPL on Plasminogen
This figure displays a representative example of the immunoprecipitation of plasm
anti-plasminogen antibody. The x-axis shows the molar ratio of antibody to plasmin
immunoprecipitation. (B) OxPL/plasminogen in the supernatant. (C) Lp(a) level in
other abbreviations as in Figures 1 and 2.
Figure 4 OxPL on Coagulation Factors With Kringle-Like Moiet
Evaluation of the content of PC-OxPL on coagulation factors with kringle-like struct
vator (tPA), and urokinase were captured in microtiter wells by immunocapture from
with monoclonal antibody E06. ***p  0.001 compared with the other groups. ANut not after 120 days and 7 months (Fig. 8B). In contrast,
here were no significant changes in plasminogen levels and
xPL/plasminogen in normal individuals (p  0.86 and p 
.98 by ANOVA, respectively) and patients with stable CAD
p  0.46 and p  0.31 by ANOVA, respectively) over time.
For comparison between groups, significant differences were
noted at the 30-day time point for both plasminogen and
OxPL/plasminogen, but not at the other time points. Plas-
minogen and OxPL/plasminogen levels did not correlate with
Lp(a), OxPL/apoB, or OxPL/apo(a) levels (data not shown).
Discussion
This study demonstrates that plasminogen is a major carrier
of OxPL in plasma of humans and animals, and OxPL
g Immunoprecipitation
from plasma in a healthy individual with the addition of increasing amounts of
content added. (A) Plasminogen levels remaining in the supernatant following
atant. (D) OxPL/apo(a) levels in supernatant. Mab  monoclonal antibody;
y double-capture ELISA. Plasminogen, prothrombin, tissue-type plasminogen acti-
ma of 6 healthy individuals, and then the content of PC-OxPL was determined
analysis of variance; other abbreviations as in Figures 1 and 2.Usin
inogen
ogen
supernies
ures b
plas
OVA 
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Using Density Gradient Ultracentrifugation
Density gradient ultracentrifugation from a patient with an Lp(a) plasma level of
90 mg/dl was used to isolate 24 fractions ranging in density 1.000 to 1.189
g/ml, and an aliquot of each fraction was assessed by ELISA for plasminogen
(A), OxPL/plasminogen (B), Lp(a) (C), OxPL/apo(a) (D), apoB (E), and OxPL/
apoB (F). Abbreviations as in Figures 1 and 2.Figure 6 Plasminogen and OxPL/Plasminogen from
FH Patients With Different Plasma Lp(a) Levels
Plasma from 15 familial hypercholesterolemia (FH) patients with varying Lp(a)
levels was assessed by ELISA for Lp(a) (A), OxPL/apo(a) (B), plasminogen (C),
and OxPL/plasminogen (D). Additionally, the bottom fraction was also
assessed for plasminogen (E) and OxPL/plasminogen (F). *p  0.05 and
***p  0.001 compared with the other groups as indicated. Abbreviations as
in Figures 1 and 2.
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plasminogen are distinct from the OxPL present on Lp(a)
and represent the second major pool of OxPL in plasma.
Unlike OxPL/apoB and OxPL/apo(a) levels, which vary
widely and which were previously shown to correlate with
plasma Lp(a) levels (3,9), OxPL/plasminogen levels are
distributed in a very narrow range and do not change over
time among healthy subjects and patients with stable CAD.
However, they rise acutely in patients following AMI.
These findings may link atherogenic and thrombotic pro-
cesses in defining the presence of OxPL as a unifying
pathophysiological link among Lp(a) and plasminogen.
Glu-plasminogen is the zymogen that is converted to the
active protease “plasmin” by cleavage of Arg561-Val562
resulting in an N-terminal heavy chain of 561 amino acids
and a disulfide-linked C-terminal light chain of 230 amino
acids. Plasmin can also activate glu-plasminogen to lys-
plasminogen by removing the first N-terminal 77 amino
acids in a positive feedback reaction. The catalytic triad of
plasmin consists of His603, Asp646, and Ser741. Kringles I
and IV participate in binding to lysine residues present on
the surface of fibrin or cell membranes. We now present
Figure 7 In Vitro Fibrin Clot Lysis of Native Plasminogen Conta
In vitro clot lysis assay assessing the ability of plasminogen to degrade fibrin c
gen with OxPL enzymatically removed (inset) with phospholipase A2 were used
is marked by an initial rapid increase in turbidity, as measured by absorbance
nal to baseline levels. The parameter tm (transition midpoint) is taken as the s
that is halfway between the minimum and maximum excursions. The curves re
bance at 405 nm every 5 s.evidence in a variety of animal models, healthy humans, andpatients with CAD and ACS that plasminogen is a major
carrier of a distinct pool of OxPL within the non-
lipoprotein fraction of plasma that is not associated with
Lp(a). The LC-MS/MS results demonstrate that the OxPC
covalently modify plasminogen. The precursor ion scanning
experiments were carried out on peptides using a collision
energy of 35 V that are indicative of the covalent nature of
these modifications. One would expect that noncovalent
association of PC species with plasminogen would not
survive the stringent condition of denaturing, reduction, and
digestion. Furthermore, disruption of noncovalent interac-
tion in a collision-induced dissociation experiment requires
much less energy. Finally, the demonstration that saponifi-
cation removed the PC from the peptides is consistent with
the postulated Schiff base formation between lysines of the
protein and the reactive oxidized moieties present on the
sn-2 side chains of the OxPL (20).
Although phospholipid surfaces are needed to activate
clotting cascades, the role of OxPL in these pathways is not
well defined. The few studies published in this area are not
entirely consistent, but on the whole, suggest free OxPL
species promote a pro-coagulant shift on the endothelium
OxPL And Plasminogen With OxPL Removed Enzymatically
Native plasminogen containing oxidized phospholipids (OxPL) and plasmino-
is system, thrombin-induced clot formation occurs within the first 2 min and
nm. Subsequent clot lysis is indicated by a rapid return of the turbidity sig-
rd measure of lysis time and is defined as the time point on the lysis curve
t the mean  SEM of 3 separate experiments with measurement of absor-ining
lots.
. In th
at 405
tanda
presenand mediate blood clotting (21). In addition, OxPL in
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through a CD36 scavenger receptor pathway in platelets
(22). The current study suggests for the first time to our
knowledge that OxPL on plasminogen are also important in
facilitating fibrinolysis, as their removal results in a longer
clot lysis time. This removal of OxPL may result in a
decreased rate of plasminogen activation or a decreased
enzymatic activity of plasmin. It may be postulated that the
presence of OxPL on plasminogen may facilitate activation
of plasminogen to plasmin by tPA and other plasminogen
activators. Furthermore, the OxPL on plasminogen may
bind to scavenger receptors on cells that are recruited at sites
of inflammation, atherosclerosis, and thrombosis. It remains
to be defined what percent of circulating plasminogen
contains covalently bound OxPL and what their relative
contributions to fibrinolysis are. In contrast, Lp(a) has been
shown to inhibit fibrinolysis in vitro (18,23,24), but the
specific role of the OxPL component on Lp(a) on fibrino-
Figure 8 Change in Plasminogen and OxPL/Plasminogen in No
(A) Baseline levels and changes in plasminogen levels over a 7-month period
coronary artery disease (CAD) (n  17), and in healthy subjects (n  18). (B)
p values at the bottom of the figures represent the discharge (average of 4 da
each time point. *p  0.05 and **p  0.01 represent Bonferroni post test folysis has not been investigated. The overall role of OxPL onplasminogen and Lp(a) in mediating all aspects of fibrino-
lysis awaits further dedicated mechanistic studies.
In vitro tissue culture studies have shown that the gene
expression of plasminogen can increase significantly when
cells are exposed to inflammatory mediators, such as IL-6
(25). In the current study, we demonstrate for the first time
in serial time points that both plasminogen and OxPL/
plasminogen levels were significantly lower at baseline in
patients with AMI compared with stable CAD and normal
subjects, but increase acutely following the proinflammatory
milieu of AMI in subjects treated with percutaneous coronary
intervention. Although this AMI study is small and hypothesis
generating, it does imply that OxPL/plasminogen may vary
before and following plaque rupture and thrombosis and
that they may play a role in either thrombosis and fibrino-
lysis, the extent of reperfusion, and perhaps long-term
clinical outcomes. An acute increase in plasminogen levels
post-AMI was previously documented, although the clinical
Subjects, Patients with Stable CAD and AMI
ents after acute myocardial infarction (AMI) (n  8), in patients with stable
ne levels and changes in OxPL/plasminogen over the same time period. The
the AMI group) and 30-, 120-, and 210-day differences between groups at
ges within groups over time. Abbreviations as in Figures 1, 2, and 4.rmal
in pati
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r chanimplications remain undefined (26). Interestingly, a similar
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ies to oxidized low density lipoprotein (OxLDL) were
previously noted in the same subjects, as well as in percu-
taneous coronary intervention patients in another cohort
(6,12). Since plasminogen (like apoB) is usually in excess to
apo(a), except in cases of very high Lp(a) levels, it suggests
that plasminogen may represent a larger carrier of OxPL
than Lp(a). We are currently evaluating the changes in
OxPL/plasminogen and plasminogen in large ACS studies
and assessing their predictive value.
Interestingly, animal and human studies have suggested,
but not proven definitively, that elements of the fibrinolytic
system may have proatherogenic properties (27). In fact,
experimental studies have suggested that plasminogen me-
diates proatherogenic effects in mouse models (28,29).
Although these data need confirmation, one may postulate
that some of these effects may be mediated through the
OxPL and CD36 macrophage scavenger receptor pathway
(30,31). The presence of OxPL on plasminogen may also
activate smooth muscle cells, enhance endothelial cells
growth, or induce release of proinflammatory cytokines that
theoretically may be beneficial in injured tissues, but detri-
mental in atherosclerotic lesions. The identification of
specific lysine receptors on a number of cell surfaces and
bacteria have implicated plasminogen in additional func-
tions such as facilitating tissue remodeling, enhancing
wound healing, mediating angiogenesis and embryogenesis,
and inhibiting infection, tumor growth, and metastasis (1).
The presence of OxPL on plasminogen may mediate
clearance of such pathogens by recruiting additional arcs of
the innate immune system, such as natural antibodies,
scavenger receptors, C-reactive protein, and potentially,
Lp(a), which has also been postulated to be involved in
wound healing (1,32). Plasminogen-deficient patients (33)
and murine models of plasminogen deficiency support many
of these functions of plasminogen manifested by diffuse
fibrin deposition leading to multiple organ failure (34,35).
Substantial experimental, clinical, and genetic evidence
have established Lp(a) as an independent risk factor for
premature CAD, death, myocardial infarction, stroke, and
peripheral arterial disease, although the mechanisms under-
lying its proatherogenic potential are not fully established
(3–5). Lp(a) has also been shown to inhibit the fibrinolytic
properties of plasminogen in vitro through several mecha-
nisms, including inhibiting tPA-mediated activation of
glu-plasminogen (18,24), inhibition of plasminogen and
tPA lysine-dependent binding to fibrin surfaces (36), and
inhibiting the action of plasmin in converting glu-
plasminogen to the activated form lys-plasminogen (23).
In a large series of clinical and experimental studies (9),
we have established that a key component of the athero-
genicity of Lp(a) and its value in predicting new cardio-
vascular events (3,13) may be its unique property, among
lipoproteins, to preferentially bind and transport proin-
flammatory OxPL. Measuring OxPL on apoB particles
(OxPL/apoB), which primarily reflects OxPL on Lp(a),appears to uniquely measure the biological activity and
proatherogenic potential of Lp(a), particularly of the
most atherogenic small isoforms of apo(a) associated with
high Lp(a) levels (14). As opposed to plasminogen, Lp(a)
contains, not only covalently bound OxPL, but also
OxPL present in its lipid phase (10).
It appears that only Lp(a) and plasminogen contain
significant amounts of OxPL in plasma proteins, as no other
immunoreactive bands can be seen in immunoblots of all
species tested. There was no evidence that plasminogen was
attached to OxPL-containing Lp(a) or apoB particles cir-
culating in plasma. Kringles of the plasminogen-prothrombin
gene family share conformational epitopes with each other and
with apo(a), but plasminogen and Lp(a) are the only kringle-
containing structures containing OxPL, although all coagula-
tion and growth factors were not tested in this study. This
suggests that it is not the kringle structures per se that mediate
OxPL binding, but other as yet unidentified motif(s) common
to both apo(a) and plasminogen. Edelstein et al. (37) recently
reported that commercial and cell culture sources of human
plasminogen contained covalently bound OxPL as detected by
several techniques, including immunoreactivity of the antibody
T15 (37), which our group initially demonstrated to be
identical in the variable region to the IgM E06 (38), inorganic
phosphate analysis, and presence of lyso-PC from plasminogen
following treatment with lipoprotein-associated phospholipase
A2. Their study did not evaluate non-human sources of
lasminogen or evaluate its role in lipoprotein disorders and
VDs, nor did it differentiate Lp(a)/apo(a) versus plasminogen
ools in plasma. Studies are underway to define the specific
inding sites and amino acids on plasminogen and Lp(a) that
ind OxPL. This would also allow a determination of the
ffinity and relative proportion of plasminogen molecules that
arry OxPL.
onclusions
ur findings demonstrate that plasminogen contains cova-
ently bound OxPL and that plasminogen represents a
econd major pool of OxPL in human plasma in addition to
p(a). OxPL on plasminogen seem to facilitate fibrinolysis
nd that patients with ACS develop elevated levels of both
lasminogen and OxPL/plasminogen. The presence of
xPL on plasminogen may have pathophysiological impli-
ations in atherothrombosis and clinical events and await
uture basic and clinical investigations.
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APPENDIX
For an expanded Methods section and supplemental figure,
please see the online version of this paper.
